Elixir Associates reposted this
Headhunting Talented Individuals within Clinical Operations & Clinical Development for growing organizations across the US & Europe
Artiva Biotherapeutics is looking to raise up to $135 million from an Initial Public Offering (IPO) to fund clinical trials for its leading allogeneic natural killer (NK) cell therapy. The San Diego-based company revealed these plans in a recent Securities and Exchange Commission filing, with expectations of selling 8.7 million shares priced between $14 and $16 each 💰 💵 The major focus for the proceeds will be on advancing the clinical development of AlloNK, a non-genetically modified, cryopreserved NK cell therapy. Currently, AlloNK is being tested in a phase 1 trial for lupus nephritis alongside Roche's Rituxan or Gazyva. It's also part of another study that spans multiple autoimmune indications. By the first half of 2025, we should see some promising data readouts 📉 #Biotechnology #ArtivaBiotherapeutics #ClinicalTrials #NKCellTherapy #IPO #LifeScience #ElixirAssociates #StaffingPartner
